CD8 T lymphocytes from immunologically stable HIV-1-infected secrete a soluble factor — termed CAF —, which suppresses HIV-1 replication, but the exact identity of CAF has been unclear. In September ...
MedPage Today on MSN
FDA Approves New Standalone Combo Pill for HIV
Islatravir-doravirine matched alternate regimens in two phase III trials ...
In a recent study published in the journal PLOS Biology, researchers in France investigated the cellular function and antiviral role of human SAMD9L and its paralog SAMD9 (short for sterile alpha ...
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...
Merck’s Idvynso, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir gets US FDA approval for the treatment of HIV-1 infection: Rahway, New Jersey ...
It was previously demonstrated that the HIV-1 integrase (IN)-interacting host factor INI1/SMARCB1 binds to HIV-1 IN through its Rpt1 domain of INI1 (INI1-Rpt1) and plays a key role in assembly and ...
By Christy Santhosh and Sriparna Roy April 21 (Reuters) - The U.S. Food and Drug Administration has approved Merck's ...
HIV-1 infection, in combination with other antiretrovirals, in treatment-experienced adults with evidence of viral replication and HIV-1 strains resistant to multiple antiretrovirals. Raltegravir ...
The CC-chemokines RANTES, macrophage inflammatory protein 1α (MIP-1α), and MIP-1β are natural ligands for the CC-chemokine receptor CCR5. This receptor is used by human immunodeficiency virus type 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results